Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

PYX-201 Receives Orphan Drug Designation From the FDA in Pancreatic Cancer

May 12th 2023

The FDA has granted an orphan drug designation to PYX-201 for the treatment of patients with pancreatic cancer.

Dr Gibson on Current and Emerging Biomarkers in Gastric/GEJ Adenocarcinoma

May 11th 2023

Michael K. Gibson MD, PhD, discusses current and emerging biomarkers in the treatment of patients with gastric or gastroesophageal junction adenocarcinoma.

Adjuvant Atezolizumab and Bevacizumab Delays Recurrence in Early-Stage HCC

May 10th 2023

Ahmed O. Kaseb, MD, discusses how the previous approval of atezolizumab and bevacizumab in hepatocellular carcinoma provided the impetus for the IMBrave050 study, how data from this study could support the regimen’s approval in the adjuvant setting, and how this approval could substantially improve the treatment landscape for early-stage disease.

FDA Grants Orphan Drug Status to RAD 301 for Imaging of Pancreatic Ductal Adenocarcinoma

May 10th 2023

The FDA has granted an orphan drug designation to RAD 301 for the imaging of patients with pancreatic ductal adenocarcinoma.

Dr Holowatyj on the Potential Role of Germline Genetic Features in Appendiceal Cancer Susceptibility

May 8th 2023

Andreana N. Holowatyj, PhD, MSCI, discusses results from an investigation of germline genetic features that may confer cancer susceptibility in patients with appendiceal cancer.

Dr Malalur on Addressing Unmet Needs in Pancreatic Cancer

May 8th 2023

Pannaga G. Malalur, MBBS, discusses several unmet needs within pancreatic cancer, including the implementation of updated germline genetic testing guidelines, increased screening of high-risk patients, and improved sequencing of available therapeutics.

Dr Noonan on Challenges Regarding the Sequencing and Selection of Therapies in HCC

May 5th 2023

Anne M. Noonan, MBBCh, discusses unmet needs that remain to be addressed in hepatocellular carcinoma, including challenges regarding the navigation and sequencing of treatment options

Dr Noonan on Practice-Changing Trials in HCC

April 27th 2023

Anne M. Noonan, MBBCh, discusses recent practice-changing trials for the treatment of patients with hepatocellular carcinoma.

Taking Organoids From Bench to Bedside Through Endoscopy in Pancreatic Cancer: Ongoing Research

April 27th 2023

In this seventh episode of OncChats: Taking Organoids From Bench to Bedside Through Endoscopy in Pancreatic Cancer, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Richard Burkhart, MD, discuss ongoing research such as the PASS-01 trial (NCT04469556) in pancreatic cancer and ways to translate advances in the metastatic setting to the curative setting.

Dr Kaseb on the Investigation of Adjuvant Atezolizumab and Bevacizumab in Early-Stage HCC

April 21st 2023

Ahmed O. Kaseb, MD, discusses the significance of results from the phase 3 IMbrave050 trial of adjuvant atezolizumab and bevacizumab for patients with early-stage hepatocellular carcinoma.

Taking Organoids From Bench to Bedside Through Endoscopy in Pancreatic Cancer: Expectations for the Future

April 21st 2023

In this fifth episode of OncChats: Taking Organoids From Bench to Bedside Through Endoscopy in Pancreatic Cancer, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Richard Burkhart, MD, provide insight into some of the regulatory challenges of organoid development and share expectations for the future of pharmacotyping in treatment selection.

Tislelizumab Plus Chemotherapy Meets OS End Point in Advanced Gastric/GEJ Adenocarcinoma

April 21st 2023

The combination of tislelizumab plus chemotherapy elicited a statistically significant and clinically meaningful improvement in overall survival compared with chemotherapy plus placebo in patients with advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

Endoscopic Strategies Broaden the Pancreatic Cancer Diagnostic and Treatment Paradigms

April 20th 2023

In pancreatic cancer, the role of the endoscopist continues to evolve as technologies like endoscopic ultrasound–guided biopsies present clinicians with increasingly accurate information to characterize the tumor microenvironments of individual patients and determine effective targeted therapies.

Taking Organoids From Bench to Bedside Through Endoscopy in Pancreatic Cancer: Sensitivity of Endoscopic Ultrasound and Cross-Sectional Imaging

April 20th 2023

In this fifth episode of OncChats: Taking Organoids From Bench to Bedside Through Endoscopy in Pancreatic Cancer, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Richard Burkhart, MD, review the potential advantages of using endoscopic ultrasound to enhance current molecular diagnostic techniques in pancreatic cancer.

Hemostatic Radiotherapy Represents Tool for Management of GI Bleeding in Advanced Cancer

April 18th 2023

Hemostatic radiation is a method of managing bleeding in patients with gastrointestinal cancers or GI metastases from other primary tumors; however, a multidisciplinary team is required to implement this method, according to Marnee M. Spierer, MD, MBA.

Pembrolizumab Plus Cisplatin/Gemcitabine Extends OS in Advanced Biliary Tract Cancer

April 16th 2023

Pembrolizumab plus cisplatin and gemcitabine produced a statistically significant and clinically meaningful improvement in overall survival vs placebo plus cisplatin and gemcitabine in previously untreated patients with advanced biliary tract cancer, according to data from the phase 3 KEYNOTE-966 trial.

Adjuvant Atezolizumab Plus Bevacizumab Significantly Improves RFS in High-risk HCC

April 16th 2023

Adjuvant treatment with the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) resulted in a statistically significant and clinically meaningful improvement in recurrence-free survival vs active surveillance in patients with a high risk of hepatocellular carcinoma recurrence following curative-intent resection or ablation.

Taking Organoids From Bench to Bedside Through Endoscopy in Pancreatic Cancer: Success of Growing Organoids

April 14th 2023

In this fourth episode of OncChats: Taking Organoids From Bench to Bedside Through Endoscopy in Pancreatic Cancer, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Richard Burkhart, MD, shed light on the process of obtaining sufficient tissue through endoscopic ultrasound–guided biopsies to generate organoids.

Taking Organoids From Bench to Bedside Through Endoscopy in Pancreatic Cancer: Organoid Collection

April 13th 2023

In this third episode of OncChats: Taking Organoids From Bench to Bedside Through Endoscopy in Pancreatic Cancer, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Richard Burkhart, MD, highlight the three ways in which an organoid can be used to aid clinical sequencing and treatment selection in pancreatic cancer.

FDA Accepts sBLA for Pembrolizumab Plus Chemotherapy in Advanced Gastric/GEJ Adenocarcinoma

April 13th 2023

The FDA has accepted for review a supplemental biologics license application for pembrolizumab plus fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.